• Tayyab Saeed Akhter
  • Muhammad Umar Department of Medicine, Holy Family Hospital, *Research Unit, Rawalpindi Medical College and Allied Hospitals, Rawalpindi
  • Hammama-Tul-Bushra Khaar Department of Medicine, Holy Family Hospital
  • Faiza Aslam Department of Medicine, Holy Family Hospital
  • Gul Nisar Department of Medicine, Holy Family Hospital
  • Aqsa Naseer Department of Medicine, Holy Family Hospital
  • Sadia Ahmad Department of Medicine, Holy Family Hospital
  • Muhammad Osama Department of Medicine, Holy Family Hospital


Background: This study was conducted to determine the viral responses of patients with chronic infection of Hepatitis C virus treated with sofubuvir. Methods: This Quasi experimental study was conducted at Centre for Liver and Digestive Diseases, Holy Family Hospital, Rawalpindi from September 2014 to September 2016. 502 patients with HCV genotype 3 including treatment naive, non-responders or relapsers to previous interferon based therapy along with patients having decompensated cirrhosis (child class B or C) were included in the study. All patients were treated with Sofosbuvir 400 mg once daily along with Ribavirin for 6 months.  Follow-up qualitative PCR (polymerase Chain Reaction) were performed at 4 weeks interval to assess RVR (Rapid virological Response), end of treatment to determine ETR (End of treatment response) and 3 months post treatment to determine SVR12 (Sustained viral response at 12 week). Results: 91% of the patients had become PCR negative at completion of four weeks of treatment with Sofosbuvir, whereas at completion of treatment 96.5% had attained a negative PCR. Sustained virological response at 12 weeks post therapy (SVR12) was attained in 85.5% of patients. No statistically significant associations were found with attainment status of RVR, ETR and SVR based on previous treatment status or presence of Decompensated liver disease. However, attainment of SVR was slightly more in females (p value=0.03). The serological profiles of patients whether they attained PCR at week 4, 24 of treatment or 12 weeks’ post treatment did not exhibit any statistically significant difference. Conclusion: Sofosbuvir is effective in eradicating hepatitis C virus irrespective of previous treatment or liver fibrosis status in genotype 3 HCV Pakistani patients.Keywords: Sofosbuvir; Hepatitis C virus; infection; Polymerase chain reaction; virology; Genotype


Gower E, Estes C, Blach S, Shearer KR, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):45–57.

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335–74.

Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315(25):1575–8.

Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136(4):288–92.

Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002:36(5 Suppl 1):S237–44.

Highlights of prescribing informatION These highlights do not include all the information needed to use SOVALDI safely and effectively. [Internet]. [cited 2016 Aug 30]. Available from:

Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics-A Randomized Clinical Trial. JAMA 2013;310(8):804–11.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C. N Engl J Med 2013;368(1):34–44.

Lai CL, Wong VWS, Yuen MF, Yang JC, Knox SJ, Mo H, et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther 2016;43(1):96–101.

Zeuzem S , Dusheiko GM , Salupere R, Mangia A, Flisiak R, Hyland R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013;58(4):733–4.

Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015;7(12):6716–29.

LawitzE, Mangia A ,Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection . N Engl J Med 2013;368(20):1878–87.

Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867–77.

Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61(4):1127–35.

Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. Gastroenterology 2015;149(6):1462–70.

Mangia A, Piazzolla V. Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. Dig Liver Dis 2014;46(5):S179–85.

Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 2008;47(6):1884–93.

Farooqi JI, Humayun M, Chaudhry A, Sadik M, Din Z, Alam A, et al. Multi-center experience using Sofosbuvir & Ribavirin with and without pegylated interferon to treat hepatitis C patients with and without liver cirrhosis (RESiP Study: Real-life Experience with Sofosbuvir in Pakistan) [abstract accepted for AASLD 2016 #2548704].

Akram M, Idrees M, Zafar S, Hussain A, Butt S, Afzal S, et al. Effect of host and virus related factors on interferon alpha plus ribavirin and pegylated interferon plus ribavirin treatment outcomes in chronic hepatitis C patients. Virol J 2011;8(1):234–6.

Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I, et al. Evaluation of prognostic factors for peg interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infect Genet Evol 2011;11(3):640–5.

Umar M, Khaar HU, Khan SA, Ahmed M, Ambreen S, Minhas ZM, et al. Early predictability of virological response in patients of chronic hepatitis- C with genotype-3, treated with pegylated interferon and ribavirin. J Ayub Med Coll Abbottabad 2014;26(4):559–63.

Qureshi MS, Iqbal M, Nomani AZ, Rasheed K. Time for Change: Conventional Interferon Regimes Should Not Be the Standard of Care for Management of Pakistani Genotype-3 in Chronic Hepatitis C. J Coll Physicians Surg Pak 2014;24(1):70–2.

Fateen F, Yousaf MN, Khan N, Nouman F, Iqbal W, Siraj S. Therapy success rate with pegylated interferon/ribavirin treatment of relapse and non-responder hepatitis c patients. Adv Basic Med Sci 2015;1(1):11–5.

Recommendations for Testing, Managing, and Treating Hepatitis C [Internet]. [cited 2016 Aug 30]. Available from:

Reddy R, Lim JK, Kuo A, Di Bisceglie A, Vargas H, Galati J, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-TARGET. J Hepatol 2015;62(Suppl 2):S193.

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol 2014;60(4):741–7.

Belci P, Collo A, Martorana M, Evangelista A, Giunti S, Gambino R, et al. Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study. Hepatoma Res 2016;2(2):122–30.

Bhattacharya D, Umbleja T, Carrat F, Chung RT, Peters MG, Torriani F, et al. Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 2010;55(2):170–5.

Ruggieri A, Malorni W. Gender Disparity in Hepatitis: A New Task in the Challenge against Viral Infection. J Hepat Res 2015;2(3):1028.

Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, et al. Restoration of HCV-specific CD8+ T-cell function by interferon-free therapy. J Hepatol 2014;61(3):538–43.

Maini MK, Schurich A. Direct-acting antivirals trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance. J Hepatol 2014;61(3):459–61.

Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 2016;151(1):70–86.

Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Symonds WT, et al. Sofosbuvir in combination with pegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013;58(Suppl 1):1380A.

Gane EJ, Hyland RH, An D, Svarovskaia ES, Pang PS, Symonds WT, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. In WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2014. p.1274A–5.



Most read articles by the same author(s)